Nektar Therapeutics vs Tango Therapeutics
NKTR and TNGX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How NKTR and TNGX compare
Tango Therapeutics is the larger company, worth 3.3 times as much as Nektar Therapeutics ($4.1B against $1.2B).
Tango Therapeutics grew revenue faster over the last twelve months (121% versus −43.9% for Nektar Therapeutics).
Tango Therapeutics keeps more of each dollar of sales as profit, with a net margin of −230% compared with −297% at Nektar Therapeutics.
Tango Therapeutics scores higher on the StockData Score (10 against 9 for Nektar Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | NKTR | TNGX |
|---|---|---|
| Size and price | ||
| Market cap | $1.2B | $4.1B |
| Share price | $36.44 | $24.17 |
| Change, 1 year | −32.5% | 213% |
| Change, 5 years | −78.3% | 134% |
| Beta (5Y) | 0.63 | 1.55 |
| Employees | 63 | 137 |
| StockData Score | ||
| Total score | 9 | 10 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 2 | 2 |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 22.5× (better) | 75.7× |
| P/B | 1.4× (better) | 4.0× |
| FCF yield | −16.8% | −3.5% (better) |
| Fair value | – | $9.65 |
| Margin of safety | – | −150% |
| Growth | ||
| Revenue growth (TTM) | −43.9% | 121% (better) |
| Revenue growth, 5Y average | −18.4% | 52.1% (better) |
| Profitability | ||
| Gross margin | 100% | – |
| Operating margin | −254% | −253% (better) |
| Net margin | −297% | −230% (better) |
| FCF margin | −378% | −268% (better) |
| Return on equity | −37.3% | −21.3% (better) |
| Return on invested capital | −1186% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 10.42 | 50.82 (better) |
| Altman Z-score | −0.67 | 49.39 (better) |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Buyback yield | 0.00% | – |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 105% | 127% |
| Held by insiders | 0.46% | 11.7% |
| Insider net buying, 12 months | −$2.2M (better) | −$8.1M |
| Short interest, % of float | 19.9% | 32.4% |
Go deeper
- NKTR stock overview
- NKTR income statement
- NKTR valuation and score
- TNGX stock overview
- TNGX income statement
- TNGX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.